{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T12:06:26Z","timestamp":1765713986310,"version":"3.40.5"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"abstract":"<jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Lobaplatin is a new platinum-based cytotoxic chemotherapeutic agent. Endostar is an endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate the efficacy and safety of thoracic perfusion of lobaplatin combined with endostar in the treatment of malignant pleural effusions (MPE).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched the databases of Pubmed, the Cochrane Library, Embase, WanFang Data, and CNKI to select the studies regarding the efficacy and safety of lobaplatin combined with endostar to treat MPE. A total of 10<jats:sup>[3\u201312]<\/jats:sup> randomized controlled trials with 651 patients were included.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The objective response rate (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, odds ratio = 4.08) and disease control rate (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, odds ratio = 3.69) of lobaplatin combined with endostar were significantly higher than lobaplatin alone. In addition, lobaplatin combined with endostar remarkably promoted the quality of life of patients (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .001, odds ratio = 3.93) compared with lobaplatin alone. Lobaplatin combined with endostar also promoted the quality of life of patients (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05, odds ratio = 2.56) compared with cisplatin combined with endostar. At the same time, the leukopenia rate (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05, odds ratio = .40) and the incidence of nausea and vomiting (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05, odds ratio = .38) of lobaplatin combined with endostar were significantly lower than that of cisplatin combined with endostar.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The efficacy of lobaplatin combined with endostar was superior to lobaplatin alone. The safety was higher than cisplatin combined with endostar through thoracic perfusion in treating MPE, which indicated that lobaplatin combined with endostar could be the effective agent for controlling MPE.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000030749","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T14:54:38Z","timestamp":1665413678000},"page":"e30749","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Thoracic perfusion of lobaplatin combined with endostar for treating malignant pleural effusions: A meta-analysis and systematic review"],"prefix":"10.1097","volume":"101","author":[{"given":"Cheng-Qian","family":"Wang","sequence":"first","affiliation":[{"name":"The Second Medical College, Binzhou Medical University, Yantai, China"},{"name":"Department of Thoracic Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5641-120X","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12890-017-0451-1","article-title":"Diagnostic value of medical thoracoscopy in malignant pleural effusion.","volume":"17","author":"Wu","year":"2017","journal-title":"BMC Pulm Med"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e011480","DOI":"10.1136\/bmjopen-2016-011480","article-title":"Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentral randomized study of aggressive versus symptom-guided drainage via indwelling pleural catheters.","volume":"6","author":"Azzopardi","year":"2016","journal-title":"BMJ Open"},{"key":"R3-20250504","first-page":"540","article-title":"Clinical observation of intrapleural infusion of Endostar combined with lobaplatin in the treatment of malignant pleural effusion.","volume":"18","author":"Wen","year":"2011","journal-title":"Biomed Eng Clin Med"},{"key":"R5-20250504","first-page":"42","article-title":"Clinical effect of recombinant human endostatin injection combined with lobaplatin in the treatment of malignant pleural effusion.","volume":"8","author":"Li","year":"2016","journal-title":"Chin J Front Med Sci"},{"key":"R6-20250504","first-page":"804","article-title":"Effect observation and prognosis analysis of recombinant human endostatin combined with lobaplatin in the treatment of malignant pleural effusion.","volume":"20","author":"Yin","year":"2020","journal-title":"Eval Anal Drug-Use Hospitals China"},{"key":"R7-20250504","first-page":"153","article-title":"Efficacy of Endostar combined with Lobaplatin in the treatment of malignant pleural effusion in non-small cell lung cancer.","volume":"16","author":"Shi","year":"2016","journal-title":"World Latest Med Information"},{"key":"R8-20250504","first-page":"186","article-title":"Clinical effect of endostar combined with lobaplatin in the treatment of malignant pleural effusion.","volume":"7","author":"Ji","year":"2020","journal-title":"Electronic J Pract Gynecol Endocrinol"},{"key":"R9-20250504","first-page":"8","article-title":"Analysis of the efficacy and adverse reactions of lobaplatin combined with Endostar by pleural infusion in the treatment of non-small cell lung cancer complicated with malignant pleural effusion.","volume":"51","author":"Chen","year":"2021","journal-title":"Qinghai Med J"},{"key":"R10-20250504","first-page":"152","article-title":"Clinical observation on the treatment of malignant pleural effusion by pleural infusion of lobaplatin combined with Endostar.","volume":"9","author":"Du","year":"2017","journal-title":"Chin J Oncol Prevent Treatment"},{"key":"R11-20250504","first-page":"1694","article-title":"Clinical study of intrapleural infusion of lobaplatin combined with Endostar in the treatment of non-small cell lung cancer with malignant pleural effusion.","volume":"38","author":"Wen","year":"2018","journal-title":"Int J Respiration"},{"key":"R12-20250504","first-page":"41","article-title":"Clinical study of intrapleural infusion of lobaplatin combined with recombinant human endostatin in the treatment of malignant pleural effusion of lung cancer.","volume":"11","author":"Cao","year":"2012","journal-title":"J Dali Univ"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"7335","DOI":"10.1158\/1078-0432.CCR-04-0183","article-title":"Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.","volume":"10","author":"Davidson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.lungcan.2012.03.006","article-title":"VEGF and sVEGFR-1 in malignant pleural effusions: association with survival and pleurodesis outcomes.","volume":"77","author":"Hooper","year":"2012","journal-title":"Lung Cancer"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.3892\/or.2013.2349","article-title":"Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer- mediated malignant pleural effusion.","volume":"29","author":"Du","year":"2013","journal-title":"Oncol Rep"},{"key":"R16-20250504","first-page":"2939","article-title":"Vascular endothelial growth factor in plasma and pleural effusion is a biomarker for outcome after bevacizumab plus carboplatin-paclitaxel treatment for non-small cell lung cancer with malignant pleural effusion.","volume":"36","author":"Tamiya","year":"2016","journal-title":"Anticancer Res"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/1759-7714.12115","article-title":"Incidence and clinical implication of tumor cavitation in patients with advanced non-small cell lung cancer induced by Endostar, an angiogenesis inhibitor.","volume":"5","author":"Huang","year":"2014","journal-title":"Thoracic Cancer"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12032-014-0410-0","article-title":"Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice.","volume":"32","author":"Fang","year":"2015","journal-title":"Med Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"8637","DOI":"10.7314\/APJCP.2015.16.18.8637","article-title":"Intraperitoneal perfusion therapy of endostar combined with platinum chemotherapy for malignant serous effusions: a meta-analysis.","volume":"16","author":"Liang","year":"2015","journal-title":"Asian Pacific J Cancer Prevent"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:39:54Z","timestamp":1746333594000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":18,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030749","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}